The results of surgical treatment for intrahepatic cholangiocarcinoma (ICC) and specific factors influencing survival are unclear.
Researchers from Japan assessed 62 patients with ICC who underwent laparotomy, between 1984 and 2001. Of these 48 patients were resectable.
The research team retrospectively reviewed tumors in the 48 patients, to examine the relationship between gross appearance and patient survival, as well as the manner of recurrence.
Furthermore, in patients with mass-forming, and mass-forming plus periductal infiltrating types, univariate and multivariate analyses of potential prognostic factors were performed.
The team found 1-, 3- and 5-year survival rates to be 62%, 38% and 23%, respectively.
|1-, 3- and 5-year survival rates were 62%, 38% and 23%, respectively.|
|British Journal of Surgery|
Survival in patients with the intraductal growth type ranged between 8 and 72 months.
Using univariate analysis, the team found multiple hepatic lesions, liver capsule invasion, presence of cancer cells in the resection margin, and high serum carbohydrate antigen (CA) 19-9 level to be significant negative prognostic factors.
However, they did not identify lymph node involvement as a significant prognostic factor.
With multivariate analysis, multiple hepatic lesions and high serum CA19-9 concentration were found to be significantly related to prognosis.
In addition, the team determined that the most frequent recurrence site was the remnant liver.
Dr Ohtsuka ’s team concluded, “These results suggest that the intraductal growth type of tumor should be treated as a distinct entity compared with other types of ICC”.
“Multiple tumors and high serum CA19-9 level were signs of dismal prognosis, whereas not all patients with lymph node involvement had a poor prognosis”.